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Background: Amyotrophic lateral sclerosis (ALS) is a fatal progressive neurodegenerative disease with no available
therapy. Components of the innate immune system are activated in the spinal cord and central nervous system of
ALS patients. Studies in the SOD1G93A mouse show deposition of C1q and C3/C3b at the motor end-plate before
neurological symptoms are apparent, suggesting that complement activation precedes neurodegeneration in this
model. To obtain a better understanding of the role of complement at the motor end-plates in human ALS
pathology, we analyzed post-mortem tissue of ALS donors for complement activation and its regulators.
Methods: Post-mortem intercostal muscle biopsies were collected at autopsy from ALS (n = 11) and control (n = 6)
donors. The samples were analyzed for C1q, membrane attack complex (MAC), CD55, and CD59 on the motor
end-plates, using immunofluorescence or immunohistochemistry.
Results: Here, we show that complement activation products and regulators are deposited on the motor end-plates
of ALS patients. C1q co-localized with neurofilament in the intercostal muscle of ALS donors and was absent in
controls (P = 0.001). In addition, C1q was found deposited on the motor end-plates in the intercostal muscle. MAC was
also found deposited on motor end-plates that were innervated by nerves in the intercostal muscle of ALS donors but
not in controls (P = 0.001).
High levels of the regulators CD55 and CD59 were detected at the motor end-plates of ALS donors but not in controls,
suggesting an attempt to counteract complement activation and prevent MAC deposition on the end-plates before
they are lost.
Conclusions: This study provides evidence that complement activation products are deposited on innervated motor
end-plates in the intercostal muscle of ALS donors, indicating that complement activation may precede end-plate
denervation in human ALS. This study adds to the understanding of ALS pathology in man and identifies complement
as a potential modifier of the disease process.
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Amyotrophic lateral sclerosis (ALS) is the most common
adult-onset motor neuron disease [1]. It is characterized
by progressive loss of both upper and lower motor neu-
rons, leading to muscle atrophy and eventually death [2].
Most ALS cases (90 %) are sporadic, while 10 % are
familial. Many genes have been identified for familial
ALS;C9orf72, FUS, TARDBP are the most frequently af-
fected genes. Mutations in the gene encoding for the* Correspondence: f.baas@amc.nl
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in about 10 % of familial cases of the disease. The trans-
genic SOD1G93A rodent model recapitulates onset and
progression of ALS.
The mechanisms leading to ALS are still unclear; both
cell autonomous and non-cell autonomous mechanisms
are involved [3–5]. A role of neuroinflammation [6–8] and
early involvement of the neuromuscular junction in the
SOD1G93A rodent model has been suggested [9, 10]. The
complement system has been also associated with neuroin-
flammation in the ALS rodent model [8, 11]. Complement
is a key component of the innate immunity, but it can cause
harm to tissue. Regulators of the complement systems article is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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ing the host. When this balance is disrupted, complement
activation causes injury to the host and contributes to path-
ology in various diseases [12–14].
A role for complement in the pathogenesis of ALS in
man is suggested by different researchers. Elevated con-
centrations of complement activation products in serum
and cerebrospinal fluid were detected in ALS patients.
In the spinal cord and motor cortex of patients with
sporadic ALS, mRNA for C1q, C4 and protein levels of
complement proteins C1q, C3, and membrane attack
complex (MAC) were elevated [15]. In addition, C1q
and C4 were upregulated in motor neurons in murine
ALS models [16, 17], whereas C3 was upregulated in the
anterior horn areas containing motor neuron degener-
ation [11]. Other studies have also shown upregulation of
the major proinflammatory C5a receptor, during disease
progression in mouse motor neurons [18]. SOD1G93A rat
treated with C5aR antagonist displayed a significant exten-
sion of survival time and a reduction in end-stage motor
scores, suggesting an important role for complement in
the disease progression [11]. Increased expression of com-
plement components C1qB, C4, factors B, C3, and C5 and
a decrease in the expression of regulators CD55 (regulator
of C3) and CD59a (regulator of MAC) was detected in the
lumbar spinal cord of SOD1G93A mice [19].
We have previously shown that complement activation
products C3/C3b and C1q were present at the motor
end-plates of SOD1G93A mice before the appearance of
symptoms and remained detectable at the symptomatic
stage, suggesting that complement activation precedes
neurodegeneration and plays an early role in this model
[20]. Early damage at the end-plates is in line with the
“dying-back” mechanism. Retrograde degeneration is de-
tected in ALS patients [21, 22], and in transgenicTable 1 Demographic and clinical data of ALS donors
Patient nr Gender Age of onset PMD
1 F 66 6
2 F 61 Unk
3 M 56 10
4 F 80 Unk
5 M 68 Unk
6 F 57 9.5
7 M 62 Unk
8 M 72 Unk
9 M 68 Unk
10 M 54 Unk
11 F 58 10–1
All the cases analyzed show classical pathology with motor cell loss and degenerat
inclusions in motor cells
PMD post-mortem delay
aC9ORF repeatSOD1G93A mice, retraction of motor axons from their
muscle synapse has been shown to occur before any
symptoms of the disease appear in the muscle [23], sug-
gesting the disease starts at the motor end-plates.
Here, we analyzed whether key complement compo-
nents and regulators are also deposited at the motor
end-plates in post-mortem intercostal muscles of human
ALS cases. We tested for the presence of complement
components C1q and MAC and for the regulators CD55
and CD59 in this tissue.Methods
Ethics statements
Tissue was obtained and used in accordance with the
Declaration of Helsinki and the Academic Medical
Center Research Code provided by the Medical Ethics
Committee. Informed consent was obtained from all
the patients.Tissue processing human intercostal muscle
Post-mortem intercostal muscle biopsies were collected at
autopsy from sex-matched ALS (n = 11) and control (n = 6)
donors at the Department of Neuropathology of the
Academic Medical Center (University of Amsterdam). All
cases were reviewed by a neuropathologist and diagnosed
according to the standard histopathological criteria. None
of our patients were on respiratory support. Muscle sam-
ples were snap-frozen in liquid nitrogen and stored at
−80 °C until processed. Detailed information about sex,
age, and clinical features of ALS and control donors are
given in Tables 1 and 2. In this study, we included material
from ALS donors with familial and sporadic ALS. We
used age-matched controls, which did not suffer from
neuromuscular or neurological disease. The tissue was(hours) Disease duration (years) ALS type
4.5 Sporadic ALS
nown 1 Sporadic ALS
3.5 Sporadic ALS
nown 2 Sporadic ALS
nown 3.5 Familial ALSa
3.5 Sporadic ALS
nown 4 Sporadic ALS
nown X Sporadic ALS
nown 3.5 Sporadic ALS
nown 1.5 Familial ALSa
1 2 Sporadic ALS
ion of the corticospinal tracts, including P62 and phosphorylated TDP43
Table 2 Demographic and clinical data control donors
Patient nr Gender Age PMD (hours)
1 M 69 5–6
2 F 65 Unknown
3 F 55 3.5–4
4 M 73 11
5 M 62 4–8
6 F 68 10
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temperature compound (OCT) (Sakura, Zoeterwoude,
NL) and cut using cryostat (Reichert Jung; Leica,
Nussloch, Germany); cryosections of 6 and 40-μm were
cut and stored at −80 °C until immuno- and fluorescence
stainings were performed.
Nonspecific esterase reaction followed by
immunostaining
Fresh frozen sections of 6 μm were tested for the nonspe-
cific esterase (NE) reaction according to the technique of
Lehrer and Ornstein [24]. After the NE staining, the sec-
tions were fixed for 10 min in 4 % paraformaldehyde
(PFA) and after washed in PBS. The sections were per-
meabalized in PBS/0.2 % TritonX and blocked for 1 h at
room temperature (RT) using PBS/5 % fetal calf serum
(FCS)/0.2 % TritonX (blockmix). The primary antibodies
anti-C5b-9 for MAC recognizes a neo-epitope in C9
(aE11 clone, Dako, Carpinteria, CA), anti-C1q (Dako, F
0254, Denmark), or anti-decay-accelerating factor (anti-
DAF) (Abcam, Ab20145, Cambridge, MA, USA) were
diluted in blockmix according to Table 3 and incubated
for 1 h at room temperature. The sections were washed
with PBS three times and incubated with the secondary
antibody PowerVision poly-AP anti-mouse IgG or poly-AP
anti-rabbit IgG (Immunologic, DPVM55A, Netherlands)
for 45 min. After washing, the sections were developed withTable 3 Primary antibodies and their dilutions
Antigen Species Specificity
Neurofilament heavy chain (NF-H) Rabbit polyclonal Anti-neurofi
MAC (ae11 clone) Mouse monoclonal Anti-C5b-9 c
FITC-conjugated C1q complement Polyclonal rabbit Anti-C1q
FITC-conjugated DAF Mouse monoclonal Anti-CD55
CD59 Mouse monoclonal Anti-CD59
C1q Polyclonal rabbit Anti-C1q
FITC-conjugated C3c complement Polyclonal rabbit Anti-C3
DAF Mouse monoclonal Anti-CD55
Synaptophysin Rabbit monoclonal Anti-synapto
Synaptophysin Mouse monoclonal Anti-synapto
S100b Rabbit polyclonal Anti-S100b
S100b Mouse monoclonal Anti-S100bVECTOR Blue Alkaline Phosphatase (AP) Substrate Kit
(SK-5300). The sections were air-dried and mounted using
VectaMount (Vector laboratories, H-5000-60, USA).
Animals
SOD1G93A transgenic ALS mice [high copy number;
B6SJLTg (SOD1-G93A)1Gur/J] (Gurney, 1994b) and
wild-type (B6SJL) littermates were housed in groups at
20 °C on 12:12 h light-dark cycle, with free access to
food and water. Experimental protocols complied with
national animal care guidelines, licensed by the respon-
sible authority. All animals were free of microbiological
infection (FELASA screened).
Tissue processing SODG93A and wild-type mice
SOD1G93A and wild-type mice were sacrificed at post-
natal day 47 (presymptomatic stage SOD1G93A n = 4;
wild-type n = 4) by CO2 inhalation. The gastrocnemius
muscle was dissected, post-fixed overnight in 4 % para-
formaldehyde/PBS at 4 °C, cryoprotected in 30 % su-
crose/PBS for 72 h at 4 °C, and embedded in Tissue-
TEK OTC; cryosections of 40-μm were cut and stored at
−80 °C until used for histology.
Immunofluorescence staining
For immunofluorescence staining of SOD1G93A gastro-
cnemius muscle and human intercostal muscle tissue,
sections were air-dried and fixed for 10 min in 4 % PFA
at −20 °C. Slides were washed in PBS and permeabalized
in PBS/0.2 % TritonX. Subsequently, sections were
blocked for 1 h at room temperature (RT) using PBS/
5 % FCS/0.2 % TritonX (blockmix). Primary antibodies
were diluted in blockmix according to Table 3 and incu-
bated overnight at 4 °C. The following primary anti-
bodies were used (see Table 3 for specifications): anti-
neurofilament heavy-chain (NF-H, Abcam, Cambridge
UK) nerves, anti-synaptophysin detecting the motorType Dilution Art.#/company
lament Anti-human 1:1000 ab8135/Abcam
omplex Anti-human 1:200 M0777/Dako
Anti-human 1:50 F0254/Dako





physin Anti-human 1:50 RM-9111-S/Thermo Scientific
physin Anti-human 1:200 M0776/Dako
Anti-human 1:100 Z0311/Dako
Anti-human 1:500 S2532/Sigma
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M0776/Dako, Carpinteria, CA), anti-S100b recognizing
the terminal Schwann cells (Z0311/Dako, Carpinteria,
CA or S2532/Sigma, USA), anti-C5b-9 for MAC (aE11
clone, Dako, Carpinteria, CA), anti-C1q-FITC conju-
gated (DAKO, Denmark), anti-C3c-FITC conjugated rec-
ognizing C3c part of C3 and C3b, anti-DAF-FITC
conjugated detecting the regulator of complement CD55
(BD Pharmingen), and anti-CD59 detecting the regulator
of MAC (Hycult Biotech). The sections were washed in
PBS, and secondary antibodies was applied, diluted ac-
cording to Table 4 in blockmix, and incubated for 2 h at
RT. Used secondary antibodies are anti-mouse FITC
(Jackson Immunoresearch, West Grove, PA), anti-rabbit
and anti-mouse Cy3 (Jackson Immuno Research, West
Grove, PA), and anti-mouse Cy5 (Invitrogen, Germany).
After washing off the secondary antibody, α-bungarotoxin
(α-BTX)-Alexa 488 conjugate (Molecular Probes) (1:500),
which binds to post-synaptic acetylcholine receptors on
the muscle fibers, was applied for 20 min at room
temperature to the sections to visualize the end-plates.
The sections then were washed in PBS and air-dried.
Vectashield medium (Vector Laboratories Inc, Burlingame,
USA) was used for mounting.
Microscopy
The 40-μm muscle sections were analyzed for the positivity
for fluorophores Cy3 (550–570 nm), Cy5 (649/665 nm),
and alpha-bungarotoxin-Alexa 488 (488–520 nm) using a
Leica TCS SP8 X confocal microscope (Leica Microsystems
B.V., Rijswijk, The Netherlands). For each view, Z-stacks
(objective ×40/1.30 oil; 290 μm×290 μm) of 40-μm thick
muscle tissue were made. The images were analyzed using
Leica LCS software (Leica).
Quantification
For each view, Z-stacks of 40-μm thick muscle were ex-
amined and scored on the total number of immunoreac-
tivity for Alexa 488-α-BTX/MAC, Alexa 488-α-BTX/
CD59-positive end-plates as well as the total number of
NF-H staining co-localizing with specific complement
antibodies C1q and CD55 (Table 3). For each muscle
sample of an individual donor, 20 non-overlapping
microscopic views of 40-μm thick sections were exam-






Alexa 488-α-BTX Snake 1:500Each motor end-plate identified with Alexa 488-α-
BTX on the surface of a muscle fiber was counted, and
the length of the end-plates were measured in both ALS
and control muscle biopsies. The size of end-plates was
measured using Leica application suite X software
(LASX software, Microsystems B.V., Rijswijk, The
Netherlands) 3D visualizer, excluding the end-plates that
were not completely in the 3D image. The number of
immunoreactive area per section was scored and
expressed as standard deviation of the mean (SD).
Statistical analysis
Data analysis was performed using GraphPad Prism ver-
sion 5.0 (GraphPad Software Inc, San Diego, CA, USA)
statistical package. Student’s t test was performed for
statistical analyses comparing two groups. For compari-
son of more than two groups, one-way ANOVA with
Bonferroni multiple comparison post hoc test was used
when the data was normally distributed. For non-
normally distributed data, the Kruskal-Wallis test was
used. Differences were considered statistically significant
when P ≤ 0.05.
Results
Motor end-plates in ALS intercostal muscle
The size and number of motor end-plates were analyzed
in the intercostal muscle of ALS donors and age- and
sex-matched controls. For analysis of both nerves and
motor end-plates, confocal microscopy was performed
on 40-μm thick intercostal muscle sections of ALS and
control donors that were stained for Alexa 448 α-BTX
detecting the motor end-plates and neurofilament
heavy-chain antibody (NF-H). Alexa 448 α-BTX positive
and negative end-plates were expected in the intercostal
muscle of ALS post-mortem tissue given that the aver-
age age of the ALS donors was 64 years and that failure
of the respiratory muscle occurs in the end-stage of the
disease in these patients. All control muscles showed
co-localization of α-BTX and NF-H. The BTX-positive
end-plates were divided in two groups: (1) end-plates
co-localizing with NF-H (innervated) (Fig. 1a, b) and (2)
end-plates that showed no co-localization with NF-H
(denervated) (Fig. 1c).
The average number of α-BTX-positive end-plates in
the intercostal muscles were 87 in controls and 17 ine
Art.#/company Excitation/emission
Jackson Immuno Research/200-542-037 493/519
Jackson Immuno Research/200-162-037 550/570
Jackson Immuno Research/711-165-152 550/570
Invitrogen/A10524 649/665
Anti-nicotinic acetylcholinereceptor 495/519
Fig. 1 Number and size of α-BTX-positive end-plates in intercostal muscle of ALS donors. Confocal microscopic images of motor end-plates from
controls (a) and ALS donors (b, c) double-labeled with α-bungarotoxin (α-BTX, Alexa 488) and antibodies against neurofilament (NF-H, Cy3). All
controls showed co-localization of NF-H with α-BTX (white arrows). In ALS, both innervated end-plates (panel b) and denervated end-plates (panel
c) were detected. The number and size of α-BTX-positive end-plates in 20 non-overlapping Z-stacks in 40-μm thick intercostal muscle sections is
shown in panels d and e. Both number and size of α-BTX-positive end-plates of ALS donors (n= 2) are reduced compared to controls (n= 2) (P= 0.0003
and P=<0.0001, respectively). Error bars represent standard deviation of the mean
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Thus, the intercostal muscle of ALS donors showed a
significantly lower number of α-BTX-positive motor
end-plates (P = 0.0003) (Fig. 1d). The percentage of in-
nervated and denervated end-plates were 30 and 70 %,
respectively, whereas the control donors show 100 % in-
nervation. We also analyzed the size of the α-BTX-
positive end-plates in the intercostal muscle of two ALS
patients and two age-matched controls. The controls
showed a mean of 16.9 μm [SD 4,34) (n = 2), and the ALS
cases showed a mean of 11.10 μm [SD 6,44) (P = <0.0001)
(n = 2) (Fig. 1e). All end-plates in the 20 non-overlapping
views were counted.
C1q deposition on the motor end-plates in the intercostal
muscle of ALS donors
C1q deposits were detected before the appearance of
clinical symptoms at the muscle end-plate of the
SOD1G93A mouse model [20]. This suggests that com-
plement activation is an early event. Here, we tested in
an overview experiment whether C1q deposits are also
present in the muscle of ALS donors and if C1q is spe-
cifically deposited on the motor end-plate. Immuno-
fluorescence for NF-H and C1q was performed on theintercostal muscle of control (Fig. 2a, b, c) and ALS
(Fig. 2d, e, f ) donors. For each individual, we analyzed
20 non-overlapping Z-stacks in 40-μm thick sections
using confocal microscopy. C1q immunoreactivity was
present in the majority of the intercostal muscle tissue
of ALS donors (Fig. 2d, e, f ). An average of 14 [control
vs ALS P = 0.001) of the C1q immunoreactive regions in
the intercostal muscle of ALS donors were co-localizing
with NF-H staining (Fig. 2g, black bar). An additional 20
areas [control versus ALS P = 0.001) of the C1q immu-
noreactivity were found in the vicinity of NF-H staining
(Fig. 2g, gray bar). No C1q immunoreactivity was de-
tected in the intercostal muscle of age-matched controls
(Fig. 2b). The NF-H immunoreactivity was generally
stronger in the intercostal muscles of control compared
to ALS donors (data not shown).
To determine whether C1q is deposited on the end-
plates, we performed a NE staining on frozen intercostal
muscles of control and ALS donors to visualize the end-
plates followed by an immunostaining for C1q. The immu-
nostaining showed an extensive amount of C1q deposited
on and around the end-plates of ALS donors (Fig. 2i). No
C1q deposition was detected in on the end-plates of control
donors (Fig. 2h). We also detected C1q on the cellular
Fig. 2 Confocal microscopic images of intercostal muscle from controls (a, b, c) and ALS donors (d, e, f) double-labeled with antibodies against
neurofilament (NF-H, Cy3) and antibodies against classical pathway component of the complement system C1q (C1q, FITC). C1q deposition was
detected on the nerves as well as near the nerve endings (white asterisks in f) in muscle of ALS donors but not in controls. g Quantification
showed C1q-positive staining co-localizing with nerves and in the vicinity of nerve endings (white arrowhead pointing to NF-H and asterisk on
C1q in f) in the intercostal muscle of ALS donors but not in controls (P = 0.001 and P = 0.001, respectively). NE staining (dark brown) followed by
an immune staining for C1q (blue) showed (i) C1q deposition on the end-plates of ALS donors (white arrow in i and enlargement of the area as
insert) (h) by contrast, no C1q deposition was found deposited on the motor end-plates in the intercostal muscle of control donors. Numbers of
C1q-positive nerve endings in 20 non-overlapping Z-stacks in 40-μm thick intercostal muscle sections is given on the y-axis. Error bars represent
standard deviation of the mean. n.d. not detected
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deposited at the motor nerve terminal and terminal
Schwann cell in the intercostal muscle of ALS donors
(Additional file 1: Figure S1B, D, arrows) but not in controls
(Additional file 1: Figure S1A, C).
MAC deposition on the motor end-plates in the intercostal
muscle of ALS donors
To determine whether the terminal pathway of the com-
plement system is also activated in ALS, we tested for
MAC deposition at the motor end-plates. We analyzed
the intercostal muscle of ALS donors. The presence of
MAC on innervated or denervated motor end-plates was
measured using immunofluorescence and confocal micros-
copy on 40-μm thick sections. We analyzed 20 non-
overlapping Z-stacks. Human intercostal muscles of control
(Fig. 3a, b, c, d) and ALS donors (Fig. 3e, f, g, h) were
stained for NF-H, α-BTX detecting end-plates, and C9neo
epitope, a component of the terminal complement complexMAC (C5b9). MAC immunoreactivity was detected on and
around nerves and on motor end-plates in ALS patients
(Fig. 3e, f, g, h). A strong MAC immunoreactiviy was de-
tected (Fig. 3h, asterisks within insert) on the end-plates
with a weak α-BTX immunoreactivity (Fig. 3h, arrow within
insert). By contrast, a weak MAC immunoreactivity (Fig. 3h,
asterisks) was detected on end-plates with strong α-BTX
immunoreactivity (Fig. 3h, arrow) and nerves innervating
the motor end-plate (Fig. 3h, arrow head). We suggest there
might be a relevant anti-correlation between MAC and
α-BTX immunoreactivity in the ALS samples. However, the
high variability between the biological specimens and the
low number of end-plates detected in these samples make
it difficult to draw firm conclusions based on the measure-
ment of fluorescence intensities.
No MAC immunoreactivity was detected on or around
the end-plates of control donors (Fig. 3c, d). Quantifica-
tion showed a mean of six innervated (controls vs ALS
donors P = 0.01) and 11 denervated (control versus ALS
Fig. 3 Representative confocal images of triple-immunofluorescence staining for neurofilament (NF-H, Cy3), motor end-plates with α-BTX (Alexa
488), and complement component C5b-9 with MAC (Cy5) in control (a, b, c, d) and ALS intercostal muscle (e, f, g, h), shows presence of MAC
(white asterisks in h and enlarged in the insert) on end-plates (white arrows in h) and around nerves in ALS muscle (white arrowhead in h) but not
in controls (c, d). Quantification showed a significantly higher percentage of MAC-positive innervated end-plates (P= 0.001) and denervated end-plates
(P= 0.001) in ALS intercostal muscle compared to controls. Numbers of MAC-positive end-plates in 20 non-overlapping Z-stacks in 40-μm thick intercostal
muscle sections is given on the y-axis. Error bars represent standard deviation of the mean (i). NE staining (dark brown) followed by an immune staining for
MAC (blue) showed (k) MAC deposition deposited on the end-plates of ALS donors (white arrow in k enlarged in the insert), j but not on
end-plates of control donors. n.d. not detected
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non-overlapping Z-stacks in 40-μm thick intercostal
muscle sections (Fig. 3i).
To determine whether MAC is deposited on the motor
end-plates, we performed immunostainings for MAC
followed by NE staining on the intercostal muscle of con-
trol (Fig. 3j) and ALS donors (Fig. 3k). We found MAC
deposition on the motor end-plates in the intercostal
muscle of ALS donors but not in controls, suggesting that
the terminal pathway of the complement system is acti-
vated on the motor end-plates. We also detected MAC on
the cellular elements synaptophysin and S100b indicating
that MAC is also deposited at the motor nerve terminal
and terminal Schwann cell in the intercostal muscle of
ALS donors (Additional file 2: Figure S2B, D, arrows) but
not in controls (Additional file 2: Figure S2A, C).CD55 on the motor end-plates in the intercostal muscle
of ALS donors
Regulators such as CD55 and CD59 protect tissues
against an attack by the complement system. The role of
these regulators in the pathogenesis in ALS is of interest.
CD55 acts on the membranes of self-cells to circumvent
the deposition of C3b on their surfaces [25]. We found
C3/C3b deposition in the intercostal muscle of ALS do-
nors deposited at the motor nerve terminal and terminal
Schwann cells (Additional file 3: Figure S3B, D, arrows)
but not in controls (Additional file 3: Figure S3A, C).
Therefore, we analyzed whether CD55 is also deposited
in the intercostal muscle ALS donors. We analyzed 20
non-overlapping Z-stacks in 40-μm thick sections using
confocal microscopy. Human intercostal muscles of con-
trol (Fig. 4a, b, c) and ALS donors (Fig. 4d, e, f ) were
Fig. 4 Representative confocal double-immunofluorescence for neurofilament (NF-H, Cy3) and CD55 detected with anti-DAF (FITC) in control
(a, b, c) and ALS (d, e, f) intercostal muscle shows CD55 deposition in ALS intercostal muscle on and around nerves (white asterisks on CD55 and
arrowhead pointing to NF-H in f) but not in control tissue (c). Quantification showed CD55 deposition co-localizing with nerves or in the vicinity
of nerves in the intercostal muscle of ALS donors but not in controls (P = 0.01 and P = 0.0001, respectively) (g). Numbers of CD55-positive end-plates in
20 non-overlapping Z-stacks in 40-μm thick intercostal muscle sections is given on the y-axis. Error bars represent standard deviation of the mean n.d.
not detected. NE staining (dark brown) followed by an immune staining for CD55 (blue) showing i CD55 deposition on the motor end-plates (white
arrow in i) in the intercostal muscle of ALS donors h but no CD55 deposition in controls
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ing for CD55 on and around nerves in the intercostal
muscle of ALS donors (Fig. 4f ) but not in controls
(Fig. 4c). Quantification showed a significantly higher
percentage of CD55-positive staining. Not all staining
co-localized with NF-H in the intercostal muscle of ALS
donors (Fig. 4g, gray bar).
To determine whether CD55 is deposited on the end-
plates, a NE staining on frozen intercostal muscle of
control and ALS donors was performed to visualize the
end-plates followed by immunostaining for CD55. No
CD55 deposition was detected on the end-plates of con-
trol donors (Fig. 4c, h), by contrast an extensive amount
of CD55 was found deposited on and around the end-
plates of ALS donors (Fig. 4i), suggesting an increased
regulation of the common complement pathway on the
end-plates. We also detected CD55 on the cellular ele-
ments synaptophysin and S100b indicating that CD55 is
also deposited at the motor nerve terminal and terminal
Schwann cell in the intercostal muscle of ALS donors(Additional file 4: Figure S4B, D, arrows) but not in con-
trols (Additional file 4: Figure S4A, C).
CD59 on the motor end-plates in the intercostal muscle
of ALS donor
The glycolipid anchored protein CD59 has a binding site
for both C8 and C9 and as such can prevent formation of
MAC [26, 27]. Immunofluorescence staining for NF-H, α-
BTX detecting end-plates, and the regulator CD59 was
performed on intercostal muscle of control (Fig. 5a–d)
and ALS (Fig. 5e–h) donors. We analyzed 20 non-
overlapping Z-stacks in 40-μm thick sections using con-
focal microscopy. CD59 was found abundantly present on
and around the motor end-plates in the intercostal muscle
of ALS donors (Fig. 5g, h, asterisks) but was negative in
the intercostal muscle of control donors (Fig. 5c, d).
Quantification showed that this difference is significant
for both innervated and denervated motor end-plates of
ALS donors (Fig. 5i) (P = 0.05, P = 0.05, respectively). In
addition, we show that CD59 is also deposited on the
Fig. 5 Representative confocal triple-immunofluorescence for neurofilament (NF-H, Cy3), end-plates detected with α-BTX (Alexa 488) and the
regulator CD59 (Cy5) in control (a, b, c, d) and ALS (e, f, g, h) intercostal muscle showing deposition of CD59 (white asterisks in h, enlarged in
insert) in ALS intercostal muscle tissue on denervated end-plates (white arrow pointing to α-BTX and arrowhead pointing to NF-H in h) but not in
controls. Quantification shows CD59-positive innervated and denervated motor end-plates in the intercostal muscle of ALS donors but not in controls
(P = 0.05 and P = 0.05, respectively) (i). Data represents standard deviation of the mean. n.d. not detected
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intercostal muscle of ALS donors (Additional file 5: Figure
S5B, D, arrows) but not in controls (Additional file 5:
Figure S5A, C).
Discussion
Although a role for complement has been found in
many neurodegenerative diseases [28–34], its contribu-
tion to disease progression in animal models for ALS is
controversial [35, 36]. We previously provided evidence
for an early role of the complement system in the
SOD1G93A mouse model of familial ALS [20]. Fischer
and colleagues suggest that ALS pathology starts at the
muscle end-plates proceeding to the spinal cord and
subsequently the brain [23]. In addition, several physio-
logical and morphological alterations have been reported
on the muscle end-plates from in vivo and ex vivo
mouse and rat preparations [37–43].
To obtain a better understanding of the role of com-
plement in human ALS pathology, we analyzed post-mortem tissue of ALS donors for complement activation
products and its regulators. We found a lower number
and a decreased size of the α-BTX-positive end-plates in
the tissue of ALS donors compared to controls, suggest-
ing that the end-plates in the intercostal muscle of ALS
patients are affected.
In the ALS muscle, we found deposition of comple-
ment activation products C1q and C3 but not in con-
trols. C1q and C3 were detected not only on and around
the end-plates but also on the nerve terminal and ter-
minal Schwann cells. C1q and C3 mRNA and protein
levels were found elevated in spinal cord and motor cor-
tex of patients with sporadic ALS [15]. In murine ALS
models, C1q was also upregulated in motor neurons
[16], whereas C3 is upregulated in the anterior horn
areas containing motor neuron degeneration. Expression
profiling in the mutant SOD1 motor neurons showed
that C1q genes were upregulated early in the disease.
C1q can bind antibody aggregates and activate the clas-
sic complement pathway [11, 17]. This data suggests a
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ger et al. demonstrates no significant pathogenic role for
C1q and C3 proteins in the survival of SOD1G93A ALS
mice, contradicting a possible role for complement in this
model [44]. This study, however, did not analyze down-
stream pathways, like the extrinsic pathway of complement
which can lead to C5 cleavage and does not need C1q and
C3 proteins for activation and MAC formation, which may
be the key point at which complement-mediated neurotox-
icity occurs in these ALS models [35, 45].
A role for MAC in the pathology of neurological disor-
ders is suggested, including ALS [31]. In serum of ALS
patients, the terminal complement activation products
C5a and MAC are elevated [46]. MAC can damage tis-
sue and target nerves in different neurodegenerative
models [34, 47], suggesting a role for MAC in degener-
ation. Furthermore, we show that MAC is deposited on the
motor end-plates on day 47 in the SOD1G93A mouse
model, suggesting that MAC deposition is an early event in
this model (Additional file 6: Figure S6). This result is in
contrast to a previous analysis of the SODG93A mice [20].
In that study, no MAC was detected on the end-plates of
the SODG93A mice. We attribute this difference to the use
of another antibody for the detection of C5b9. We used a
monoclonal mouse anti-human C9neo, this antibody gives
a specific signal on both frozen human and mouse sections.
It detects C9neo and not C9; therefore, it is also more spe-
cific to recognize the C9 within the MAC, whereas the
polyclonal mouse anti-rat C9 that was used previously ei-
ther gives no staining or a lot of background on frozen sec-
tions. Since we find MAC deposition consistently on end-
plates in both human and mouse muscle, an artifact is
excluded.
The present study shows deposition of MAC at the
muscle end-plates of ALS donors. We show strong
MAC immunoreactiviy on the end-plates with a weak α-
BTX immunoreactivity in the intercostal muscle of ALS
donors. By contrast, a weak MAC immunoreactivity was
detected on end-plates with strong α-BTX immunoreac-
tivity. This is compatible with a model in which MAC
deposition occurs before loss of the end-plates, in fact
MAC could be a contributor to disease progression and
end-plate pathology. In addition, MAC was also found
co-localizing with the motor nerve terminal and ter-
minal Schwann cells.
The propensity of the MAC to “drift” from the site of
activation and deposit on other sites may even result in
more damage to the muscle. In general, cells are pro-
tected from complement attack by multiple complement
regulators, preventing damage. This protection can be
overwhelmed resulting in damage to tissue and drives
inflammation [48, 49].
CD55 and CD59 restrict complement activation by
inhibiting C3/C5 convertase activities and membraneattack complex formation, respectively. In the actively
immunized experimental autoimmune myasthenia gravis
mice deficient in either CD55 or CD59, a significant in-
crease in complement deposition at the end-plates was
observed and worsened disease outcome associated with
increased levels of serum cytokines was observed [50].
We demonstrate that also the regulators of the com-
mon pathway CD55 and the terminal pathway CD59 are
deposited on the motor end-plates of ALS donors, but
not in controls. In addition, the motor nerve terminal
and terminal Schwann cells were also co-localizing with
CD55 and CD59. Upregulation of the complement regu-
lators CD55 and CD59 on the motor end-plates of ALS
patients probably is an attempt to dampen the high level
of complement activation and protect the tissue.
Since we also detected MAC deposition at the motor
end-plates of the ALS donors, the upregulation of CD55
and CD59 is not sufficient to protect the end-plates
from MAC attack.
Conclusions
In summary, we demonstrated that complement activa-
tion products C1q and MAC are deposited on motor
end-plates in post-mortem tissue of ALS donors. MAC
was found deposited on motor end-plates that were in-
nervated by nerves, indicating that complement activa-
tion may precede motor end-plate denervation.
Here, we showed that the regulators CD55 and CD59
are also expressed on the motor end-plates, indicating
an attempt to control the activation. This process is
probably not efficient enough because MAC can still be
detected on the α-BTX-positive motor end-plates. Since
a role for MAC in the pathology of neurological disor-
ders is suggested [31], detecting complement deposited
at the end-plates of ALS donors, before the end-plates
are lost, suggests that complement is an early event in
ALS and might play an important role in the motor end-
plate pathology in ALS. This observation is in line with
earlier studies suggesting a dying-back mechanism in
ALS, meaning the disease probably starts at the motor
end-plates [23]. Although this study was performed
using post-mortem intercostal muscle tissue of ALS pa-
tients and there may be some limitations to our conclu-
sions about complement being involved in motor end-
plate degeneration, this study adds to the understanding
of ALS pathology in man.
Additional files
Additional file 1: Figure S1. Representative confocal
immunofluorescence for synaptophysin (SYN-Cy3) detecting the motor
nerve terminal (A, B) or S100b (Cy3) detecting the terminal Schwann cells
(C, D) double stained with anti-C1q (FITC) in control (A, C) and ALS (B, D)
intercostal muscle shows C1q co-localizing with both synaptophysin and
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controls. (TIF 1461 kb)
Additional file 2: Figure S2. Representative confocal
immunofluorescence for synaptophysin (SYN-Cy3) detecting the motor
nerve terminal (A, B) or S100b (Cy3) detecting the terminal Schwann cells
(C, D) double stained with an antibody detecting MAC (FITC) in control
(A, C) and ALS (B, D) intercostal muscle shows MAC deposition on both
the motor nerve terminal and the terminal Schwann cells (white arrow in
B and D, respectively) but no MAC deposition in controls. (TIF 2178 kb)
Additional file 3: Figure S3. Representative confocal
immunofluorescence for synaptophysin (SYN-Cy3) detecting the motor
nerve terminal (A, B) or S100b (Cy3) detecting the terminal Schwann cells
(C, D) double stained with anti-C3c recognizing C3c part of C3 and C3b
(FITC) in control (A, C) and ALS (B, D) intercostal muscle shows C3c
co-localizing with both synaptophysin and S100b (white arrow in B
and D, respectively), but no C3c deposition in controls. (TIF 1624 kb)
Additional file 4: Figure S4. Representative confocal
immunofluorescence for synaptophysin (SYN-Cy3) detecting the motor
nerve terminal (A, B) or S100b (Cy3) detecting the terminal Schwann cells
(C, D) double stained with anti-CD55 (FITC) in control (A, C) and ALS (B, D)
intercostal muscle shows CD55 co-localizing with both synaptophysin and
S100b (white arrow in B and D, respectively) but no CD55 deposition in
controls. (TIF 1271 kb)
Additional file 5: Figure S5. Representative confocal
immunofluorescence for synaptophysin (SYN-Cy3) detecting the motor
nerve terminal (A, B) or S100b (Cy3) detecting the terminal Schwann cells
(C, D) double stained with anti-CD59 (FITC) in control (A, C) and ALS (B, D)
intercostal muscle shows CD59 deposition on both the motor nerve
terminal and the terminal Schwann cells (white arrow in B and D,
respectively) but no CD59 deposition in controls. (TIF 1202 kb)
Additional file 6: Figure S6. Representative confocal microscopy images
of the motor end-plate from wild-type (n = 4) (A) and SOD1G93A mice (n = 4)
at 47 (B), immunostained for neurofilament NF-H (white arrow head in A
and B), MAC with C5b9 (white asterisk in B), and the muscle end-plate with
α-BTX (Alexa 488), showing deposition of MAC (white asterisk in B) on the
innervated motor end-plate (white arrow pointing to NF-H co-localizing
with α-BTX) in SOD1G93A mice but not in the wild-type mice. Bar = 20 μm.
(TIF 869 kb)
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